F. Binder-foucard, Les cancers en France-Estimation nationale de l'incidence et de la mortalité par cancer en France entre 1980 et 2012. Partie 1-Tumeurs solides, Juillet, 2013.

X. Rebillard, P. Grosclaude, and N. Leone, Incidence and mortality of urological cancers in 2012 in France, Prog Urol, vol.23, pp.57-65, 2013.

A. Cowppli-bony, Survie des personnes atteintes de cancer en France métropolitaine 1989-2013. Institut National Du Cancer, 2016.

M. Sant, C. Allemani, M. Santaquilani, A. Knijn, F. Marchesi et al., EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary, Eur J Cancer, vol.45, issue.6, pp.931-91, 2009.
URL : https://hal.archives-ouvertes.fr/hal-00492650

H. B. Grossman, R. B. Natale, and C. M. Tangen, Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer, N Engl J Med, vol.349, issue.9, p.1880, 2003.

G. Sonpavde, B. H. Goldman, and S. Vo, Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy, Cancer, vol.115, pp.4104-4109, 2009.

V. Mazeau-woynar and N. Cerf, Survie attendue des patients atteints de cancers en France: états des lieux, 2010.

P. Etude, Prévention et Epidémiologie des Tumeurs en Région Ile-de-France), vol.73, p.p, 1994.

M. J. Horner, L. Ries, M. Krapcho, and N. Neyman, Cancer Statistics Review, 1975.

J. P. Stein, Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients, J. Clin. Oncol, vol.19, pp.666-675, 2001.

T. Lebret and A. Mejean, Metastases from urothelial carcinoma: role of chemotherapy, Progrès en Urologie, pp.261-276, 2008.

S. M. Donat, Staged based directed surveillance of invasive bladder cancer following radical cystectomy: valuable and effective?, World J Urol, vol.24, p.557, 2006.

J. M. Hassan, M. S. Cookson, and J. A. Smith, Patterns of initial transitional cell recurrence in patients after cystectomy, J Urol, vol.175, pp.2054-2061, 2006.

N. D. Freedman, D. T. Silverman, A. R. Hollenbeck, A. Schatzkin, and C. C. Abnet, Association between smoking and risk of bladder cancer among men and women, JAMA, vol.306, pp.737-782, 2011.

J. Gu, D. Liang, Y. Wang, C. Lu, and X. Wu, Effects of N-acetyl transferase 1 and 2 polymorphisms on bladder cancer risk in Caucasians, Mutat Res, vol.581, pp.97-104, 2005.

P. Brennan, O. Bogillot, S. Cordier, E. Greiser, W. Schill et al., Cigarette smoking and bladder cancer in men: a pooled analysis of 11 case-control studies, Int J Cancer, vol.86, pp.289-94, 2000.

E. J. Pietzak, P. Mucksavage, T. J. Guzzo, and S. B. Malkowicz, Heavy cigarette smoking and agressive bladder cancer at initial presentation, Urology, vol.86, issue.5, pp.968-72, 2015.

P. J. Bostrom, S. Alkhateeb, G. Trottier, P. Z. Athanasopoulos, T. Mirtti et al., Sex differences in bladder cancer outcomes among smokers with advanced bladder cancer, BJU Int, vol.109, pp.70-76, 2012.

. Inrs and . Cancers, Effets sur la santé

R. De-bonne-pratique, Société française de médecine du travail. Surveillance médico-professionnelle des travailleurs exposés ou ayant été exposés à des agents cancérogènes chimiques : application aux cancérogènes pour la vessie, 2012.

M. R. Abern, A. M. Dude, M. Tsivian, and C. L. Coogan, The characteristics of bladder cancer after radiotherapy for prostate cancer, Urol Oncol, vol.31, pp.1628-1662, 2013.

A. Keehn, E. Ludmir, J. Taylor, and F. Rabbani, Incidence of bladder cancer after radiation for prostate cancer as a function of time and radiation modality, World J Urol, vol.35, pp.713-720, 2017.

M. Alba, J. Moreno-palacios, S. Beça, and M. Cid, Urologic and male genital manifestations of granulomatosis with polyangiitis, Autoimmunity Reviews, vol.14, pp.897-902, 2015.

A. Berry, X. Iriart, J. Fillaux, and J. Magnaval, Urinary schistosomiasis and Cancer, Bull Soc Pathol Exot, vol.110, pp.68-75, 2017.

P. Humphrey, H. Moch, A. Cubilla, T. Ulbright, and V. Reuter, The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours, European Urology, vol.70, pp.106-119, 2016.

M. Rouprêt, Recommandations françaises du Comité de Cancérologie de l'AFU-Actualisation 2018-2020 :Tumeurs de la vessie, Progrès en Urologie, vol.28, pp.46-78, 2018.

, TNM classification of malignant tumours, 2009.

G. P. Paner and W. M. Stadler, Updates in the Eighth Edition of the Tumor-Node-Metastasis Staging Classification for Urologic Cancers, Eur Urol, vol.73, pp.560-569, 2018.

, Cancer Genome Atlas Research Network: Comprehensive molecular characterization of urothelial bladder carcinoma, Nature, vol.507, pp.315-322, 2014.

G. Sjödahl, A molecular taxonomy for urothelial carcinoma, Clin Cancer Res, vol.18, pp.3377-3386, 2012.

G. Sjödalh, Molecular classification of urothelial carcinoma: global mRNA classification versus tumour-cell phenotype classification, J Pathol, vol.242, pp.113-138, 2017.

O. Sanli, J. Dobruch, M. A. Knowles, M. Burger, M. Alemozaffar et al., Bladder cancer, Nat Rev Dis Primers, vol.3, p.17022, 2017.

J. Bellmunt, Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up, Annals of Oncology, vol.25, pp.40-48, 2014.

M. W. Kramer, I. F. Abdelkawi, M. Wolters, T. Bach, A. J. Gross et al., Current evidence for transurethral en bloc resection of non-muscle-invasive bladder cancer, Minim Invasive Ther Allied Technol, vol.23, pp.206-219, 2014.

M. Rink, M. Babjuk, J. W. Catto, P. Jichlinski, S. F. Shariat et al., Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscleinvasive bladder cancer: a critical review of the current literature, Eur Urol, vol.64, pp.624-662, 2013.

N. C. Cowan, Multidetector computed tomography urography for diagnosing upper urinary tract urothelial tumour, BJU Int, vol.99, pp.1363-70, 2007.

T. Horn, T. Zahel, . Adtn, S. C. Schmid, M. M. Heck et al., Evaluation of computed tomography for lymph node staging in bladder cancer prior to radical cystectomy, Urol Int, vol.96, pp.51-57, 2016.

O. Il, N. K. Altinbas, I. Serifoglu, E. B. Oz, and C. Yagci, The role of computerized tomography in the assessment of perivesical invasion in bladder cancer, Pol J Radiol, vol.81, pp.281-288, 2016.

V. Kundra, Imaging in the diagnosis, staging, and follow-up of cancer of the urinary bladder, AJR Am J Roentgenol, vol.180, p.1045, 2003.

M. J. Mc-kibben and &. M. Woods, Preoperative Imaging for Staging Bladder Cancer, Curr Urol Rep, vol.16, p.22, 2015.

S. Woo, C. H. Suh, Y. Kim, J. Y. Cho, and S. H. Kim, The diagnostic performance of MRI for detection of lymph node metastasis in bladder and prostate cancer: an updated systematic review and diagnostic meta-analysis, Am J Roentgenol, vol.210, pp.95-109, 2018.

G. Gakis, J. Efstathiou, and S. P. Lerner, ICUD-EAU International Consultation on Bladder Cancer 2012: radical cystectomy and bladder preservation for muscle invasive urothelial carcinoma of the bladder, Eur Urol, vol.63, pp.45-57, 2013.

A. Karl, P. R. Carroll, J. E. Gschwend, R. Knuchel, F. Montorsi et al., The impact of lymphadenectomy and lymph node metastasis on the outcomes of radical cystectomy for bladder cancer, Eur Urol, vol.55, pp.826-861, 2009.

, Advanced Bladder Cancer Meta-Analysis Collaboration: Neoadjuvant chemotherapy in invasive bladder cancer: Update of a systematic review and meta-analysis of individual patient data, Eur Urol, vol.48, pp.202-206, 2005.

M. Yin, M. Joshi, R. P. Meijer, M. Glantz, S. Holder et al., Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Two-Step Meta-Analysis, Oncologist, vol.21, pp.708-723, 2016.

C. N. Sternberg, P. H. De-mulder, and J. H. Schornagel, Randomized phase III trial of highdoseintensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924, J Clin Oncol, vol.19, pp.2638-2646, 2001.

T. K. Choueiri, S. Jacobus, and J. Bellmunt, Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: Pathologic, radiologic, and biomarker correlates, J Clin Oncol, vol.32, pp.1889-1894, 2014.

M. D. Galsky, K. Stensland, and J. P. Sfakianos, Comparative effectiveness of treatment strategies for bladder cancer with clinical evidence of regional lymph node involvement, J Clin Oncol, vol.34, pp.2627-2662, 2016.

F. Cognetti, E. M. Ruggeri, A. Felici, M. Gallucci, G. Muto et al., Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial, Ann Oncol, vol.23, pp.695-700, 2012.

C. N. Sternberg, I. Skoneczna, J. M. Kerst, P. Albers, S. D. Fossa et al., Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N + M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial, Lancet Oncol, vol.16, pp.76-86, 2015.

M. D. Galsky, K. D. Stensland, E. Moshier, J. P. Sfakianos, R. B. Mcbride et al., Effectiveness of Adjuvant Chemotherapy for Locally Advanced Bladder Cancer, J Clin Oncol, vol.34, pp.825-857, 2016.

J. J. Leow, W. Martin-doyle, P. S. Rajagopal, C. G. Patel, E. M. Anderson et al., Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials, Eur Urol, vol.66, pp.42-54, 2014.

M. I. Milowsky, R. B. Rumble, and C. M. Booth, Guideline on muscle-invasive and metastatic bladder cancer (European Association of Urology guideline, J Clin Oncol, vol.34, pp.1945-1952, 2016.

C. M. Coppin, M. K. Gospodarowicz, and K. James, Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group, J Clin Oncol, vol.14, pp.2901-2908, 1996.

N. D. James, S. A. Hussain, and E. Hall, Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer, N Engl J Med, vol.366, pp.1477-88, 2012.

O. Riou, B. Chauvet, J. Lagrange, P. Martin, C. Moscardo et al., Radiothérapie des cancers de vessie, Cancer Radiother, vol.20, pp.196-199, 2016.

O. Fahmy, M. G. Khairul-asri, T. Schubert, M. Renninger, R. Malek et al., A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer, Urol Oncol, vol.36, pp.43-53, 2018.

D. F. Bajorin, P. M. Dodd, M. Mazumdar, M. Fazzari, M. Caffrey et al., Longterm survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy, Clin Oncol, vol.17, pp.3173-81, 1999.

V. Der-maase, H. Hansen, S. W. Roberts, and J. T. , Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study, J Clin Oncol, vol.18, pp.3068-77, 2000.

M. D. Galsky, N. M. Hahn, and J. Rosenberg, Treatment of patients with metastatic urothelial cancer "unfit" for cisplatin-based chemotherapy, J Clin Oncol, vol.29, pp.2432-2470, 2011.

M. De-santis, J. Bellmunt, and G. Mead, Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: Phase II-Results of EORTC study 30986, J Clin Oncol, vol.27, pp.5634-5673, 2009.

J. Bellmunt, T. K. Choueiri, and R. Fougeray, Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens, J Clin Oncol, vol.28, pp.1850-55, 2010.

J. Bellmunt, C. Theodore, and T. Demkov, Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract, J Clin Oncol, vol.27, issue.27, pp.4454-61, 2009.

D. J. Vaughn, C. M. Broome, M. Hussain, J. C. Gutheil, and A. B. Markowitz, Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer, J Clin Oncol, vol.20, pp.937-977, 2002.

K. Kanai, E. Kikuchi, T. Ohigashi, A. Miyajima, K. Nakagawa et al., Gemcitabine and paclitaxel chemotherapy for advanced urothelial carcinoma in patients who have received prior cisplatin-based chemotherapy, Int J Clin Oncol, vol.13, pp.510-524, 2008.

J. A. Mccaffrey, S. Hilton, M. Mazumdar, S. Sadan, W. K. Kelly et al., Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma, J Clin Oncol, vol.15, pp.1853-1860, 1997.

J. Bellmunt, R. De-wit, and D. J. Vaughn, Pembrolizumab as second-line therapy for advanced urothelial carcinoma, N Engl J Med, vol.376, pp.1015-1041, 2017.

T. Powles, Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, openlabel, phase 3 randomised controlled trial, Lancet, vol.391, pp.748-757, 2018.

O. De-dreuille, P. Maszelin, H. Foehrenbach, G. Bonardel, and J. F. Gaillard, Principe et technique de la tomographie par émission de positons (TEP), Encycl Med Chir (Editions Scientifiques et Médicales Elsevier SAS, pp.1-22, 2002.

H. Young, R. Baum, U. Cremerius, K. Herholz, O. Hoekstra et al., Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group, Eur J Cancer, vol.35, pp.1773-82, 1999.

R. L. Wahl, H. Jacene, Y. Kasamon, and M. A. Lodge, From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors, J Nucl Med, vol.50, pp.122-50, 2009.

A. B. Apolo, J. Riches, H. Schöder, O. Akin, A. Trout et al., Clinical Value of Fluorine-18 2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography/Computed Tomography in Bladder Cancer, J Clin Oncol. Sept, vol.28, issue.25, pp.3973-3981, 2010.

L. S. Mertens, A. Fioole-bruining, E. Vegt, W. V. Vogel, B. W. Van-rhijn et al., Impact of 18 Fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle: FDG-PET/CT in carcinoma invading bladder muscle, BJU Int, vol.112, issue.6, pp.729-763, 2013.

P. Kollberg, H. Almquist, M. Bläckberg, C. Cronberg, S. Garpered et al., 18 F]Fluorodeoxyglucose -positron emission tomography/computed tomography improves staging in patients with high-risk muscle-invasive bladder cancer scheduled for radical cystectomy, Scand J Urol, vol.49, issue.4, pp.296-301, 2015.

Z. Yang, L. Pan, J. Cheng, S. Hu, J. Xu et al., Clinical value of whole body fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in the detection of metastatic bladder cancer, Int J Urol, vol.19, issue.7, pp.639-683, 2012.

L. S. Mertens, M. C. Mir, A. M. Scott, S. T. Lee, A. Fioole-bruining et al., 18F-fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography Aids Staging and Predicts Mortality in Patients with Muscle-invasive Bladder Cancer, Urology, vol.83, issue.2, pp.393-402, 2014.

M. Hitier-berthault, C. Ansquer, J. Branchereau, K. Renaudin, F. Bodere et al., 18 Fluorodeoxyglucose positron emission tomography-computed tomography for preoperative lymph node staging in patients undergoing radical cystectomy for bladder cancer: A prospective study: PET scan for bladder cancer, Int J Urol, vol.20, issue.8, pp.788-96, 2013.

A. S. Kibel, F. Dehdashti, M. D. Katz, A. P. Klim, R. L. Grubb et al., Prospective Study of [ 18 F] Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Staging of Muscle-Invasive Bladder Carcinoma, J Clin Oncol, vol.27, issue.26, pp.4314-4334, 2009.

A. Girard and M. Rouanne, Integrated analysis of 18 F-FDG PET/CT improves preoperative lymph node staging for patients with invasive bladder cancer, European radiology

K. Ha, H. Koo, P. J. Kim, and S. J. , Diagnostic accuracy of F-18 FDG PET/ CT for preoperative lymph node staging in newly diagnosed bladder cancer patients: a systematic review and meta-analysis, Oncology, vol.95, pp.31-38, 2018.

L. S. Mertens, A. Fioole-bruining, B. Van-rhijn, J. M. Kerst, A. M. Bergman et al., FDG-Positron Emission Tomography/Computerized Tomography for Monitoring the Response of Pelvic Lymph Node Metastasis to Neoadjuvant Chemotherapy for Bladder Cancer, J Urol, vol.189, issue.5, pp.1687-91, 2013.

A. Soubra, FDG-PET/CT for assessing the response to Neoadjuvant Chemotherapy in Bladder cancer patients, Clin Genitourin Cancer, vol.16, issue.5, pp.360-364, 2018.

A. Witjes, J. Lebret, T. Comperat, E. M. Cowan, N. C. et al., Updated 2016 EAU Guidelines on Muscle invasive and Metastatic Bladder Cancer, Eur Urol, vol.71, pp.462-75, 2017.

, NCCN Clinical Practice Guidelines in Oncology, vol.84

H. Goodfellow, Z. Viney, P. Hughes, S. Rankin, G. Rottenberg et al., Role of fluorodeoxyglucose positron emission tomography (FDG PET)-computed tomography (CT) in the staging of bladder cancer: FDG pet in the staging of bladder cancer, BJU International, vol.114, issue.3, pp.389-95, 2014.

N. Yildirim-poyraz, E. Ozdemir, B. Uzun, and S. Turkolmez, Dual phase 18F-fluorodeoxyglucose positron emission tomography/computed tomography with forced diuresis in diagnostic imaging evaluation of bladder cancer, Rev Esp Med Nucl E Imagen Mol, vol.32, issue.4, pp.214-235, 2013.

, SERMENT MEDICAL Version du Serment d'Hippocrate réactualisée et publiée dans le bulletin de l'Ordre National des Médecins, vol.4, 1996.

, Au moment d'être admise à exercer la médecine, je promets et je jure d'être fidèle aux lois de l'honneur et de la probité

, Mon premier souci sera de rétablir, de préserver ou de promouvoir la santé dans tous ses éléments, physiques et mentaux, individuels et sociaux

, Je respecterai toutes les personnes, leur autonomie et leur volonté, sans aucune discrimination selon leur état ou leurs convictions. J'interviendrai pour les protéger si elles sont affaiblies

, Même sous la contrainte, je ne ferai pas usage de mes connaissances contre les lois de l'humanité

, Je ne tromperai jamais leur confiance et n'exploiterai pas le pouvoir hérité des circonstances pour forcer les consciences

, Je ne me laisserai pas influencer par la soif du gain ou la recherche de la gloire

, Admise dans l'intimité des personnes, je tairai les secrets qui me seront confiés

, Reçue à l'intérieur des maisons, je respecterai les secrets des foyers et ma conduite ne servira pas à corrompre les moeurs

, Je ne prolongerai pas abusivement les agonies. Je ne provoquerai jamais la mort délibérément

, Je n'entreprendrai rien qui dépasse mes compétences. Je les entretiendrai et les perfectionnerai pour assurer au mieux les services qui me seront demandés

, J'apporterai mon aide à mes confrères ainsi qu'à leurs familles dans l'adversité

, Que les hommes et mes confrères m'accordent leur estime si je suis fidèle à mes promesses ; que je sois déshonorée et méprisée si j'y manque